Comorbidity and Aging With HIV

NCT01466582 · tracked via the Priya Life Science Netherlands tracker

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase

Observational

Started

2010-10

Last updated

2024-07-31

Condition(s) studied

HIV-1-infectionComorbidityAgeing

Study summary

In this prospective cohort study the investigators will assess the prevalence and incidence of a broad range of age-related co-morbidities and their (known) risk factor among HIV-patients and HIV-negative controls. HIV might cause premature onset or accelerated aging and could therefore result in an increase of age-related comorbidities when compared with controls.

Eligibility

Sex

ALL

Min age

45 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * For the HIV-positive patients: HIV-1 infection and aged 45 years and above * For the HIV-negative controls: HIV-uninfected and aged 45 years and above Exclusion Criteria: * None

Primary outcome measure(s)

The prevalence of comorbidities, organ system dysfunction and their risk factors at time of enrolment — at enrolment and after every 2 years follow up. The Ethics Committee has approved for the study to continue without a set end-date, depending on continued funding.
To assess the prevalence and incidence of comorbidities, organ system dysfunction and their risk factors over two years of follow-up in a cohort of HIV-infected individuals (mostly on antiretroviral therapy) and in a cohort of comparable but uninfected controls
The incidence of comorbidities, organ system dysfunction and their risk factors after two years of follow up — After every 2 years of follow up.The Ethics Committee has approved for the study to continue without a set end-date, depending on continued funding.
To assess the incidence of comorbidities, organ system dysfunction and their risk factors after tow years of follow up in a cohort of HIV-infected individuals (mostly on antiretroviral therapy) in comparison to that of a cohort of comparable but uninfected controls

Trial sites (2)

Facility	City	Region	Status
Public Health Service Amsterdam	Amsterdam	Netherlands
Academic Medical Center	Amsterdam	Netherlands

More Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials in the Netherlands

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY Recruiting

European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection Active, not recruiting

Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer Recruiting

Vital@Work: Reintegration Program for Employees with Stress-related Complaints Recruiting

Specifying the Anti-inflammatory Effects of Ziltivekimab Active, not recruiting

Other trials for the same condition

A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands Active, not recruiting

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 Active, not recruiting

Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01466582 on ClinicalTrials.gov ↗ ← All trials in the Netherlands